A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Cixutumumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 17 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 12 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.